Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients

Jing Li, George Cusatis, Julie Brahmer, Alex Sparreboom, Robert W. Robey, Susan E. Bates, Manuel Hidalgo, Sharyn D. Baker

Research output: Contribution to journalArticle

Abstract

The purpose of the study was to determine if the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, are substrates for the efflux transporter ABCG2, and to investigate the relevance of the ABCG2 421C>A (Q141K) polymorphism to the pharmacokinetics of gefitinib. Gefitinib and erlotinib transport in vitro was studied using HEK293 cells transfected with wild-type ABCG2 or a Q141K clone. Gefitinib pharmacokinetics was determined in 27 cancer patients. ABCG2 421C>A and ABCB1 3435C>T genotypes were determined using direct sequencing. Cells expressing wild-type ABCG2 exhibited lower intracellular accumulation of gefitinib and erlotinib at concentrations of 0.1 and 1μM, and higher efflux at 1 μM than cells lacking ABCG2 (p <0.05); no significant difference in cellular efflux and accumulation was observed in the variant cell line at lower concentrations nor in the three cell lines at 10 μM. In the presence of the ABCG2 inhibitor fumitremorgin C, cellular accumulation of gefitinib and erlotinib 1μM was increased in wild-type (p <0.05), but not in variant or null cells. Gefitinib accumulation during 28 days of treatment (Css,min/C 1,min) was higher in patients heterozygous at the ABCG2 421C>A locus than those with a wild-type genotype (median, 5.07 vs. 3.60, p = 0.004). No significant associations were observed between the ABCB1 3435C>T genotype and gefitinib pharmacokinetics. In conclusion, gefitinib and erlotinib are ABCG2 substrates, while they inhibit ABCG2 at higher concentrations. A functional variant of ABCG2 is associated with greater gefitinib accumulation at steady-state and may be relevant to toxicity and antitumor activity of EGFR TKIs.

Original languageEnglish (US)
Pages (from-to)432-438
Number of pages7
JournalCancer Biology and Therapy
Volume6
Issue number3
StatePublished - Mar 2007

Fingerprint

Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Pharmacokinetics
Neoplasms
Genotype
gefitinib
HEK293 Cells
Clone Cells
Erlotinib Hydrochloride

Keywords

  • ABCG2
  • EGFR tyrosine kinase inhibitor
  • Erlotinib
  • Gefitinib
  • Pharmacokinetics
  • Polymorphism

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. / Li, Jing; Cusatis, George; Brahmer, Julie; Sparreboom, Alex; Robey, Robert W.; Bates, Susan E.; Hidalgo, Manuel; Baker, Sharyn D.

In: Cancer Biology and Therapy, Vol. 6, No. 3, 03.2007, p. 432-438.

Research output: Contribution to journalArticle

Li, J, Cusatis, G, Brahmer, J, Sparreboom, A, Robey, RW, Bates, SE, Hidalgo, M & Baker, SD 2007, 'Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients', Cancer Biology and Therapy, vol. 6, no. 3, pp. 432-438.
Li, Jing ; Cusatis, George ; Brahmer, Julie ; Sparreboom, Alex ; Robey, Robert W. ; Bates, Susan E. ; Hidalgo, Manuel ; Baker, Sharyn D. / Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. In: Cancer Biology and Therapy. 2007 ; Vol. 6, No. 3. pp. 432-438.
@article{9b4577a3adc94b2d9b40cf043ac35f47,
title = "Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients",
abstract = "The purpose of the study was to determine if the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, are substrates for the efflux transporter ABCG2, and to investigate the relevance of the ABCG2 421C>A (Q141K) polymorphism to the pharmacokinetics of gefitinib. Gefitinib and erlotinib transport in vitro was studied using HEK293 cells transfected with wild-type ABCG2 or a Q141K clone. Gefitinib pharmacokinetics was determined in 27 cancer patients. ABCG2 421C>A and ABCB1 3435C>T genotypes were determined using direct sequencing. Cells expressing wild-type ABCG2 exhibited lower intracellular accumulation of gefitinib and erlotinib at concentrations of 0.1 and 1μM, and higher efflux at 1 μM than cells lacking ABCG2 (p <0.05); no significant difference in cellular efflux and accumulation was observed in the variant cell line at lower concentrations nor in the three cell lines at 10 μM. In the presence of the ABCG2 inhibitor fumitremorgin C, cellular accumulation of gefitinib and erlotinib 1μM was increased in wild-type (p <0.05), but not in variant or null cells. Gefitinib accumulation during 28 days of treatment (Css,min/C 1,min) was higher in patients heterozygous at the ABCG2 421C>A locus than those with a wild-type genotype (median, 5.07 vs. 3.60, p = 0.004). No significant associations were observed between the ABCB1 3435C>T genotype and gefitinib pharmacokinetics. In conclusion, gefitinib and erlotinib are ABCG2 substrates, while they inhibit ABCG2 at higher concentrations. A functional variant of ABCG2 is associated with greater gefitinib accumulation at steady-state and may be relevant to toxicity and antitumor activity of EGFR TKIs.",
keywords = "ABCG2, EGFR tyrosine kinase inhibitor, Erlotinib, Gefitinib, Pharmacokinetics, Polymorphism",
author = "Jing Li and George Cusatis and Julie Brahmer and Alex Sparreboom and Robey, {Robert W.} and Bates, {Susan E.} and Manuel Hidalgo and Baker, {Sharyn D.}",
year = "2007",
month = "3",
language = "English (US)",
volume = "6",
pages = "432--438",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "3",

}

TY - JOUR

T1 - Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients

AU - Li, Jing

AU - Cusatis, George

AU - Brahmer, Julie

AU - Sparreboom, Alex

AU - Robey, Robert W.

AU - Bates, Susan E.

AU - Hidalgo, Manuel

AU - Baker, Sharyn D.

PY - 2007/3

Y1 - 2007/3

N2 - The purpose of the study was to determine if the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, are substrates for the efflux transporter ABCG2, and to investigate the relevance of the ABCG2 421C>A (Q141K) polymorphism to the pharmacokinetics of gefitinib. Gefitinib and erlotinib transport in vitro was studied using HEK293 cells transfected with wild-type ABCG2 or a Q141K clone. Gefitinib pharmacokinetics was determined in 27 cancer patients. ABCG2 421C>A and ABCB1 3435C>T genotypes were determined using direct sequencing. Cells expressing wild-type ABCG2 exhibited lower intracellular accumulation of gefitinib and erlotinib at concentrations of 0.1 and 1μM, and higher efflux at 1 μM than cells lacking ABCG2 (p <0.05); no significant difference in cellular efflux and accumulation was observed in the variant cell line at lower concentrations nor in the three cell lines at 10 μM. In the presence of the ABCG2 inhibitor fumitremorgin C, cellular accumulation of gefitinib and erlotinib 1μM was increased in wild-type (p <0.05), but not in variant or null cells. Gefitinib accumulation during 28 days of treatment (Css,min/C 1,min) was higher in patients heterozygous at the ABCG2 421C>A locus than those with a wild-type genotype (median, 5.07 vs. 3.60, p = 0.004). No significant associations were observed between the ABCB1 3435C>T genotype and gefitinib pharmacokinetics. In conclusion, gefitinib and erlotinib are ABCG2 substrates, while they inhibit ABCG2 at higher concentrations. A functional variant of ABCG2 is associated with greater gefitinib accumulation at steady-state and may be relevant to toxicity and antitumor activity of EGFR TKIs.

AB - The purpose of the study was to determine if the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, are substrates for the efflux transporter ABCG2, and to investigate the relevance of the ABCG2 421C>A (Q141K) polymorphism to the pharmacokinetics of gefitinib. Gefitinib and erlotinib transport in vitro was studied using HEK293 cells transfected with wild-type ABCG2 or a Q141K clone. Gefitinib pharmacokinetics was determined in 27 cancer patients. ABCG2 421C>A and ABCB1 3435C>T genotypes were determined using direct sequencing. Cells expressing wild-type ABCG2 exhibited lower intracellular accumulation of gefitinib and erlotinib at concentrations of 0.1 and 1μM, and higher efflux at 1 μM than cells lacking ABCG2 (p <0.05); no significant difference in cellular efflux and accumulation was observed in the variant cell line at lower concentrations nor in the three cell lines at 10 μM. In the presence of the ABCG2 inhibitor fumitremorgin C, cellular accumulation of gefitinib and erlotinib 1μM was increased in wild-type (p <0.05), but not in variant or null cells. Gefitinib accumulation during 28 days of treatment (Css,min/C 1,min) was higher in patients heterozygous at the ABCG2 421C>A locus than those with a wild-type genotype (median, 5.07 vs. 3.60, p = 0.004). No significant associations were observed between the ABCB1 3435C>T genotype and gefitinib pharmacokinetics. In conclusion, gefitinib and erlotinib are ABCG2 substrates, while they inhibit ABCG2 at higher concentrations. A functional variant of ABCG2 is associated with greater gefitinib accumulation at steady-state and may be relevant to toxicity and antitumor activity of EGFR TKIs.

KW - ABCG2

KW - EGFR tyrosine kinase inhibitor

KW - Erlotinib

KW - Gefitinib

KW - Pharmacokinetics

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=34548240764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548240764&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 432

EP - 438

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 3

ER -